Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evaxion A/S - American Depositary Share (NQ:EVAX)

2.700 +0.120 (+4.65%)
Streaming Delayed Price Updated: 9:42 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Evaxion A/S - American Depositary Share

< Previous 1 2 Next >
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
From Evaxion Biotech
Via GlobeNewswire
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
From Evaxion Biotech
Via GlobeNewswire
Evaxion announces Executive Management Changes to strengthen the AI-strategy
From Evaxion Biotech
Via GlobeNewswire
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
From Evaxion Biotech
Via GlobeNewswire
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
From Evaxion Biotech
Via GlobeNewswire
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
From Evaxion Biotech
Via GlobeNewswire
Evaxion Announces Business Update and First Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
From Evaxion Biotech
Via GlobeNewswire
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
From Evaxion Biotech
Via GlobeNewswire
Evaxion to host R&D Day on May 25, 2023
From Evaxion Biotech
Via GlobeNewswire
Fourth quarter and full year 2022 financial results and business update
From Evaxion Biotech
Via GlobeNewswire
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
From Evaxion Biotech
Via GlobeNewswire
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
From Evaxion Biotech
Via GlobeNewswire
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
From Evaxion Biotech
Via GlobeNewswire
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
From Evaxion Biotech
Via GlobeNewswire
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
From Evaxion Biotech
Via GlobeNewswire
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
From Evaxion Biotech
Via GlobeNewswire
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
From Evaxion Biotech
Via GlobeNewswire
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
From Evaxion Biotech
Via GlobeNewswire
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
From Evaxion Biotech
Via GlobeNewswire
Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate
From Evaxion Biotech
Via GlobeNewswire
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
From Evaxion Biotech
Via GlobeNewswire
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
From Evaxion Biotech
Via GlobeNewswire
Evaxion CEO comments on strategic focus
From Evaxion Biotech
Via GlobeNewswire
Evaxion welcomes Per Norlén as new CEO.
From Evaxion Biotech
Via GlobeNewswire
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
From Personalis
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.